Early Life and Education
Xie Liangzhi, born in China, pursued higher education in the United States. He graduated from Dalian Institute of Technology (now Dalian University of Technology) with a bachelor's degree in 1987 and a master's degree in 1990. In 1996, he earned a Ph.D. in chemical engineering from the Massachusetts Institute of Technology (MIT), where he published 10 SCI papers.
Career at Merck & Co. and Return to China
After graduating from MIT, Xie joined Merck & Co. in 1996, where he worked on the development of viral vaccines. He was involved in the development and production technologies for vaccines such as Varivax®, Proquad®, and Zostavax®. During his time at Merck, Xie established advanced production technologies for the adenovirus vector AIDS vaccine. After spending 12 years in the United States, Xie decided to return to China in 2002 to start his own business.
Rise to Success with Sino Biological Inc.
In 2002, Xie founded Sino Biological Inc., a biomedical high-tech company based in the Beijing Economic and Technological Development Zone. The company focuses on the research and development of animal cell expression biotechnology products. Under Xie's leadership, Sino Biological Inc. has undertaken several scientific and technological development projects and established an advanced technology platform for large-scale animal cell cultivation and a rapid industrial channel for the pre-clinical production of genes and proteins. The company has also maintained long-term technological outsourcing service partnerships with major pharmaceutical companies.
Key Business Strategies
Xie's key business strategy involves leveraging his expertise in biotechnology and vaccine development to build a leading biopharmaceutical company. Sino Biological Inc. focuses on providing research reagents and CRO services to global pharmaceutical companies. His approach has been to establish an internationally advanced technology platform for cultivating animal cells and creating a rapid, industrialized channel for pre-clinical production of genes and proteins.
Philanthropy
While specific amounts are not readily available, Xie Liangzhi's focus is on the advancement of the biotech industry and its potential benefits to global health.